Reviews FluMist


No reviews yet.

FluMist Drug Description
FluMist®
(influenza virus vaccine live) Intranasal
DRUG DESCRIPTION



What are the possible side effects of influenza virus nasal vaccine (FluMist)?

Nasal influenza virus (live virus) vaccine may cause you to have mild flu-like symptoms. However, you may have flu-like symptoms at any time during flu season that may be caused by strains of influenza virus that are not contained in the vaccine.
You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first dose.
Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another nasal influenza...
Read All Potential Side Effects for FluMist »




FluMist (Influenza Virus Vaccine Live, Intranasal) is a live trivalent vaccine
for administration by intranasal spray. The influenza virus strains in FluMist
are (a) cold-adapted (ca) (i.e., they replicate efficiently at 25oC,
a temperature that is restrictive for replication of many wild-type influenza
viruses); (b) temperature-sensitive (ts) (i.e., they are restricted in
replication at 37oC (Type B strains) or 39oC (Type A strains), temperatures
at which many wild-type influenza viruses grow efficiently); and (c) attenuated
(att) (they do not produce classic influenza-like illness in the ferret
model of human influenza infection). The cumulative effect of the antigenic
properties and the ca, ts, and att phenotypes is that the attenuated
vaccine viruses replicate in the nasopharynx to induce protective immunity.
No evidence of reversion has been observed in the recovered vaccine strains
that have been tested (135 of possible 250 recovered isolates) [see Clinical
Studies]. For each of the three reassortant strains in FluMist, the
six internal gene segments responsible for ca, ts, and att phenotypes are derived
from a master donor virus (MDV), and the two segments that encode the two surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), are derived from the
corresponding antigenically relevant wild-type influenza viruses that have been
recommended by the USPHS for inclusion in the annual vaccine formulation. Thus,
the three viruses contained in FluMist maintain the replication characteristics
and phenotypic properties of the MDV and express the HA and NA of wild-type
viruses that are related to strains expected to circulate during the 2007-2008
influenza season. For the Type A MDV, at least five genetic loci in three different
internal gene segments contribute to the ts and att phenotypes. For the Type
B MDV, at least three genetic loci in two different internal gene segments contribute
to both the ts and att properties; five genetic loci in three
gene segments control the ca property.
Specific pathogen-free (SPF) eggs are inoculated with each of the reassortant
strains and incubated to allow vaccine virus replication. The allantoic fluid
of these eggs is harvested, pooled and then clarified by filtration. The virus
is concentrated by ultracentrifugation and diluted with stabilizing buffer to
obtain the final sucrose and potassium phosphate concentrations. In addition,
ethylene diamine tetracetic acid (EDTA) is added to the dilution buffer for
H3N2 strains. The viral harvests are then sterile filtered to produce the monovalent
bulks. Each lot is tested for ca, ts, and att phenotypes and is
also tested extensively by in vitro and in vivo methods to detect
adventitious agents. Monovalent bulks from the three strains are subsequently
blended and diluted as required to attain the desired potency with stabilizing
buffers to produce the trivalent bulk vaccine. The bulk vaccine is then filled
directly into individual sprayers for nasal administration.
Each pre-filled refrigerated FluMist sprayer contains a single 0.2 mL dose.
Each 0.2 mL dose contains 106.5-7.5 FFU of live attenuated influenza
virus reassortants of each of the three strains: A/Solomon Islands/3/2006 (H1N1),
A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 [1]. Each 0.2 mL dose also
contains 0.188 mg/dose monosodium glutamate, 2.00 mg/dose hydrolyzed porcine
gelatin, 2.42 mg/dose arginine, 13.68 mg/dose sucrose, 2.26 mg/dose dibasic
potassium phosphate, 0.96 mg/dose monosodium phosphate, and < 0.015 mcg/mL
gentamicin sulfate. FluMist contains no preservatives.
The tip attached to the sprayer is equipped with a nozzle that produces a fine mist that is primarily deposited in the nose and nasopharynx. FluMist is a colorless to pale yellow liquid and is clear to slightly cloudy.
Last reviewed on RxList: 9/26/2007




FluMist Drug Description
FluMist®
(influenza virus vaccine live) Intranasal
DRUG DESCRIPTION



What are the possible side effects of influenza virus nasal vaccine (FluMist)?

Nasal influenza virus (live virus) vaccine may cause you to have mild flu-like symptoms. However, you may have flu-like symptoms at any time during flu season that may be caused by strains of influenza virus that are not contained in the vaccine.
You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first dose.
Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another nasal influenza...
Read All Potential Side Effects for FluMist »




FluMist (Influenza Virus Vaccine Live, Intranasal) is a live trivalent vaccine
for administration by intranasal spray. The influenza virus strains in FluMist
are (a) cold-adapted (ca) (i.e., they replicate efficiently at 25oC,
a temperature that is restrictive for replication of many wild-type influenza
viruses); (b) temperature-sensitive (ts) (i.e., they are restricted in
replication at 37oC (Type B strains) or 39oC (Type A strains), temperatures
at which many wild-type influenza viruses grow efficiently); and (c) attenuated
(att) (they do not produce classic influenza-like illness in the ferret
model of human influenza infection). The cumulative effect of the antigenic
properties and the ca, ts, and att phenotypes is that the attenuated
vaccine viruses replicate in the nasopharynx to induce protective immunity.
No evidence of reversion has been observed in the recovered vaccine strains
that have been tested (135 of possible 250 recovered isolates) [see Clinical
Studies]. For each of the three reassortant strains in FluMist, the
six internal gene segments responsible for ca, ts, and att phenotypes are derived
from a master donor virus (MDV), and the two segments that encode the two surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), are derived from the
corresponding antigenically relevant wild-type influenza viruses that have been
recommended by the USPHS for inclusion in the annual vaccine formulation. Thus,
the three viruses contained in FluMist maintain the replication characteristics
and phenotypic properties of the MDV and express the HA and NA of wild-type
viruses that are related to strains expected to circulate during the 2007-2008
influenza season. For the Type A MDV, at least five genetic loci in three different
internal gene segments contribute to the ts and att phenotypes. For the Type
B MDV, at least three genetic loci in two different internal gene segments contribute
to both the ts and att properties; five genetic loci in three
gene segments control the ca property.
Specific pathogen-free (SPF) eggs are inoculated with each of the reassortant
strains and incubated to allow vaccine virus replication. The allantoic fluid
of these eggs is harvested, pooled and then clarified by filtration. The virus
is concentrated by ultracentrifugation and diluted with stabilizing buffer to
obtain the final sucrose and potassium phosphate concentrations. In addition,
ethylene diamine tetracetic acid (EDTA) is added to the dilution buffer for
H3N2 strains. The viral harvests are then sterile filtered to produce the monovalent
bulks. Each lot is tested for ca, ts, and att phenotypes and is
also tested extensively by in vitro and in vivo methods to detect
adventitious agents. Monovalent bulks from the three strains are subsequently
blended and diluted as required to attain the desired potency with stabilizing
buffers to produce the trivalent bulk vaccine. The bulk vaccine is then filled
directly into individual sprayers for nasal administration.
Each pre-filled refrigerated FluMist sprayer contains a single 0.2 mL dose.
Each 0.2 mL dose contains 106.5-7.5 FFU of live attenuated influenza
virus reassortants of each of the three strains: A/Solomon Islands/3/2006 (H1N1),
A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 [1]. Each 0.2 mL dose also
contains 0.188 mg/dose monosodium glutamate, 2.00 mg/dose hydrolyzed porcine
gelatin, 2.42 mg/dose arginine, 13.68 mg/dose sucrose, 2.26 mg/dose dibasic
potassium phosphate, 0.96 mg/dose monosodium phosphate, and < 0.015 mcg/mL
gentamicin sulfate. FluMist contains no preservatives.
The tip attached to the sprayer is equipped with a nozzle that produces a fine mist that is primarily deposited in the nose and nasopharynx. FluMist is a colorless to pale yellow liquid and is clear to slightly cloudy.
Last reviewed on RxList: 9/26/2007




FluMist Drug Description
FluMist®
(influenza virus vaccine live) Intranasal
DRUG DESCRIPTION



What are the possible side effects of influenza virus nasal vaccine (FluMist)?

Nasal influenza virus (live virus) vaccine may cause you to have mild flu-like symptoms. However, you may have flu-like symptoms at any time during flu season that may be caused by strains of influenza virus that are not contained in the vaccine.
You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first dose.
Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another nasal influenza...
Read All Potential Side Effects for FluMist »




FluMist (Influenza Virus Vaccine Live, Intranasal) is a live trivalent vaccine
for administration by intranasal spray. The influenza virus strains in FluMist
are (a) cold-adapted (ca) (i.e., they replicate efficiently at 25oC,
a temperature that is restrictive for replication of many wild-type influenza
viruses); (b) temperature-sensitive (ts) (i.e., they are restricted in
replication at 37oC (Type B strains) or 39oC (Type A strains), temperatures
at which many wild-type influenza viruses grow efficiently); and (c) attenuated
(att) (they do not produce classic influenza-like illness in the ferret
model of human influenza infection). The cumulative effect of the antigenic
properties and the ca, ts, and att phenotypes is that the attenuated
vaccine viruses replicate in the nasopharynx to induce protective immunity.
No evidence of reversion has been observed in the recovered vaccine strains
that have been tested (135 of possible 250 recovered isolates) [see Clinical
Studies]. For each of the three reassortant strains in FluMist, the
six internal gene segments responsible for ca, ts, and att phenotypes are derived
from a master donor virus (MDV), and the two segments that encode the two surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), are derived from the
corresponding antigenically relevant wild-type influenza viruses that have been
recommended by the USPHS for inclusion in the annual vaccine formulation. Thus,
the three viruses contained in FluMist maintain the replication characteristics
and phenotypic properties of the MDV and express the HA and NA of wild-type
viruses that are related to strains expected to circulate during the 2007-2008
influenza season. For the Type A MDV, at least five genetic loci in three different
internal gene segments contribute to the ts and att phenotypes. For the Type
B MDV, at least three genetic loci in two different internal gene segments contribute
to both the ts and att properties; five genetic loci in three
gene segments control the ca property.
Specific pathogen-free (SPF) eggs are inoculated with each of the reassortant
strains and incubated to allow vaccine virus replication. The allantoic fluid
of these eggs is harvested, pooled and then clarified by filtration. The virus
is concentrated by ultracentrifugation and diluted with stabilizing buffer to
obtain the final sucrose and potassium phosphate concentrations. In addition,
ethylene diamine tetracetic acid (EDTA) is added to the dilution buffer for
H3N2 strains. The viral harvests are then sterile filtered to produce the monovalent
bulks. Each lot is tested for ca, ts, and att phenotypes and is
also tested extensively by in vitro and in vivo methods to detect
adventitious agents. Monovalent bulks from the three strains are subsequently
blended and diluted as required to attain the desired potency with stabilizing
buffers to produce the trivalent bulk vaccine. The bulk vaccine is then filled
directly into individual sprayers for nasal administration.
Each pre-filled refrigerated FluMist sprayer contains a single 0.2 mL dose.
Each 0.2 mL dose contains 106.5-7.5 FFU of live attenuated influenza
virus reassortants of each of the three strains: A/Solomon Islands/3/2006 (H1N1),
A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 [1]. Each 0.2 mL dose also
contains 0.188 mg/dose monosodium glutamate, 2.00 mg/dose hydrolyzed porcine
gelatin, 2.42 mg/dose arginine, 13.68 mg/dose sucrose, 2.26 mg/dose dibasic
potassium phosphate, 0.96 mg/dose monosodium phosphate, and < 0.015 mcg/mL
gentamicin sulfate. FluMist contains no preservatives.
The tip attached to the sprayer is equipped with a nozzle that produces a fine mist that is primarily deposited in the nose and nasopharynx. FluMist is a colorless to pale yellow liquid and is clear to slightly cloudy.
Last reviewed on RxList: 9/26/2007




FluMist Drug Description
FluMist®
(influenza virus vaccine live) Intranasal
DRUG DESCRIPTION



What are the possible side effects of influenza virus nasal vaccine (FluMist)?

Nasal influenza virus (live virus) vaccine may cause you to have mild flu-like symptoms. However, you may have flu-like symptoms at any time during flu season that may be caused by strains of influenza virus that are not contained in the vaccine.
You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first dose.
Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another nasal influenza...
Read All Potential Side Effects for FluMist »




FluMist (Influenza Virus Vaccine Live, Intranasal) is a live trivalent vaccine
for administration by intranasal spray. The influenza virus strains in FluMist
are (a) cold-adapted (ca) (i.e., they replicate efficiently at 25oC,
a temperature that is restrictive for replication of many wild-type influenza
viruses); (b) temperature-sensitive (ts) (i.e., they are restricted in
replication at 37oC (Type B strains) or 39oC (Type A strains), temperatures
at which many wild-type influenza viruses grow efficiently); and (c) attenuated
(att) (they do not produce classic influenza-like illness in the ferret
model of human influenza infection). The cumulative effect of the antigenic
properties and the ca, ts, and att phenotypes is that the attenuated
vaccine viruses replicate in the nasopharynx to induce protective immunity.
No evidence of reversion has been observed in the recovered vaccine strains
that have been tested (135 of possible 250 recovered isolates) [see Clinical
Studies]. For each of the three reassortant strains in FluMist, the
six internal gene segments responsible for ca, ts, and att phenotypes are derived
from a master donor virus (MDV), and the two segments that encode the two surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), are derived from the
corresponding antigenically relevant wild-type influenza viruses that have been
recommended by the USPHS for inclusion in the annual vaccine formulation. Thus,
the three viruses contained in FluMist maintain the replication characteristics
and phenotypic properties of the MDV and express the HA and NA of wild-type
viruses that are related to strains expected to circulate during the 2007-2008
influenza season. For the Type A MDV, at least five genetic loci in three different
internal gene segments contribute to the ts and att phenotypes. For the Type
B MDV, at least three genetic loci in two different internal gene segments contribute
to both the ts and att properties; five genetic loci in three
gene segments control the ca property.
Specific pathogen-free (SPF) eggs are inoculated with each of the reassortant
strains and incubated to allow vaccine virus replication. The allantoic fluid
of these eggs is harvested, pooled and then clarified by filtration. The virus
is concentrated by ultracentrifugation and diluted with stabilizing buffer to
obtain the final sucrose and potassium phosphate concentrations. In addition,
ethylene diamine tetracetic acid (EDTA) is added to the dilution buffer for
H3N2 strains. The viral harvests are then sterile filtered to produce the monovalent
bulks. Each lot is tested for ca, ts, and att phenotypes and is
also tested extensively by in vitro and in vivo methods to detect
adventitious agents. Monovalent bulks from the three strains are subsequently
blended and diluted as required to attain the desired potency with stabilizing
buffers to produce the trivalent bulk vaccine. The bulk vaccine is then filled
directly into individual sprayers for nasal administration.
Each pre-filled refrigerated FluMist sprayer contains a single 0.2 mL dose.
Each 0.2 mL dose contains 106.5-7.5 FFU of live attenuated influenza
virus reassortants of each of the three strains: A/Solomon Islands/3/2006 (H1N1),
A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 [1]. Each 0.2 mL dose also
contains 0.188 mg/dose monosodium glutamate, 2.00 mg/dose hydrolyzed porcine
gelatin, 2.42 mg/dose arginine, 13.68 mg/dose sucrose, 2.26 mg/dose dibasic
potassium phosphate, 0.96 mg/dose monosodium phosphate, and < 0.015 mcg/mL
gentamicin sulfate. FluMist contains no preservatives.
The tip attached to the sprayer is equipped with a nozzle that produces a fine mist that is primarily deposited in the nose and nasopharynx. FluMist is a colorless to pale yellow liquid and is clear to slightly cloudy.
Last reviewed on RxList: 9/26/2007




FluMist Drug Description
FluMist®
(influenza virus vaccine live) Intranasal
DRUG DESCRIPTION



What are the possible side effects of influenza virus nasal vaccine (FluMist)?

Nasal influenza virus (live virus) vaccine may cause you to have mild flu-like symptoms. However, you may have flu-like symptoms at any time during flu season that may be caused by strains of influenza virus that are not contained in the vaccine.
You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first dose.
Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another nasal influenza...
Read All Potential Side Effects for FluMist »




FluMist (Influenza Virus Vaccine Live, Intranasal) is a live trivalent vaccine
for administration by intranasal spray. The influenza virus strains in FluMist
are (a) cold-adapted (ca) (i.e., they replicate efficiently at 25oC,
a temperature that is restrictive for replication of many wild-type influenza
viruses); (b) temperature-sensitive (ts) (i.e., they are restricted in
replication at 37oC (Type B strains) or 39oC (Type A strains), temperatures
at which many wild-type influenza viruses grow efficiently); and (c) attenuated
(att) (they do not produce classic influenza-like illness in the ferret
model of human influenza infection). The cumulative effect of the antigenic
properties and the ca, ts, and att phenotypes is that the attenuated
vaccine viruses replicate in the nasopharynx to induce protective immunity.
No evidence of reversion has been observed in the recovered vaccine strains
that have been tested (135 of possible 250 recovered isolates) [see Clinical
Studies]. For each of the three reassortant strains in FluMist, the
six internal gene segments responsible for ca, ts, and att phenotypes are derived
from a master donor virus (MDV), and the two segments that encode the two surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), are derived from the
corresponding antigenically relevant wild-type influenza viruses that have been
recommended by the USPHS for inclusion in the annual vaccine formulation. Thus,
the three viruses contained in FluMist maintain the replication characteristics
and phenotypic properties of the MDV and express the HA and NA of wild-type
viruses that are related to strains expected to circulate during the 2007-2008
influenza season. For the Type A MDV, at least five genetic loci in three different
internal gene segments contribute to the ts and att phenotypes. For the Type
B MDV, at least three genetic loci in two different internal gene segments contribute
to both the ts and att properties; five genetic loci in three
gene segments control the ca property.
Specific pathogen-free (SPF) eggs are inoculated with each of the reassortant
strains and incubated to allow vaccine virus replication. The allantoic fluid
of these eggs is harvested, pooled and then clarified by filtration. The virus
is concentrated by ultracentrifugation and diluted with stabilizing buffer to
obtain the final sucrose and potassium phosphate concentrations. In addition,
ethylene diamine tetracetic acid (EDTA) is added to the dilution buffer for
H3N2 strains. The viral harvests are then sterile filtered to produce the monovalent
bulks. Each lot is tested for ca, ts, and att phenotypes and is
also tested extensively by in vitro and in vivo methods to detect
adventitious agents. Monovalent bulks from the three strains are subsequently
blended and diluted as required to attain the desired potency with stabilizing
buffers to produce the trivalent bulk vaccine. The bulk vaccine is then filled
directly into individual sprayers for nasal administration.
Each pre-filled refrigerated FluMist sprayer contains a single 0.2 mL dose.
Each 0.2 mL dose contains 106.5-7.5 FFU of live attenuated influenza
virus reassortants of each of the three strains: A/Solomon Islands/3/2006 (H1N1),
A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 [1]. Each 0.2 mL dose also
contains 0.188 mg/dose monosodium glutamate, 2.00 mg/dose hydrolyzed porcine
gelatin, 2.42 mg/dose arginine, 13.68 mg/dose sucrose, 2.26 mg/dose dibasic
potassium phosphate, 0.96 mg/dose monosodium phosphate, and < 0.015 mcg/mL
gentamicin sulfate. FluMist contains no preservatives.
The tip attached to the sprayer is equipped with a nozzle that produces a fine mist that is primarily deposited in the nose and nasopharynx. FluMist is a colorless to pale yellow liquid and is clear to slightly cloudy.
Last reviewed on RxList: 9/26/2007





Other reviews about FluMist on wordpress

Q & A about the FluMistâ„¢ Influenza Vaccine
  by scidstuff
Get your Questions Answered about FluMistâ„¢ See our Q & A about the FluMistâ„¢ Influenza Vaccine From the IDF Newsletter, Primary Immune Tribune, Volume 1 Issue 3 Q: What is FluMistâ„¢? A: […]


FluMist Availability
  by Katy Seib
Here's a link to the CDC's Q&A about FluMist. Local Places to Get FluMist that are willing to provide to Non-Patients Grady Neighborhood Health Clinic 30 Warren Street SE Atlanta, GA  30317 404 […]


Flumist
  by vaccinefacts
What? Runny nose, sneezing, fever, sore throat, coughing, muscle aches, loss of appetite – those are not all symptoms of the flu? So, the reality is…the Flumist vaccine […]


FluMist Live H1N1 Intranasal Vaccine; Breathe Breathe, Pink Floyd
  by ahrcanum
[youtube=http://www.youtube.com/watch?v=fx6iIp-PvnY] The song Breathe from Pink Floyd is appropriate.  This this week begins the distribution of the MedImmune nasal Flu Mist®  and injectable H1N1 Swine Flu vaccines.  The Centers for Disease Control […]


H1N1 FLU MIST MAKES YOU A CARRIER OF CONTAGON FOR AT LEAST 20 DAYS
  by Dy'er Hear?
Dy'er Sez: We haven’t seen much swine flu in the US (or the world for that matter) for a while now. Considering that tens of thousands have gotten the […]


H1N1 FluMist ~ the Nasal Spray that Keeps on Giving!
  by Boulderdash
By Sherry Tomfield Everyone has to be responsible for their own decisions. If you are afraid of catching the H1N1 flu this year. You may be pondering whether to […]


The H1N1 FluMist Vaccine Contains LIVE Swine Flu Which Is Sprayed Up Your Nose
  by Tollwut
The first doses of the H1N1 swine flu vaccine are now being administered at clinics and hospitals across the United States, and many Americans are eagerly lining up […]


FluMist Recall, Third H1N1 Swine Flu Vaccine Recall
  by ahrcanum
[caption id="attachment_2500" align="aligncenter" width="163" caption="RECALLED"][/caption] MedImmune announced it is recalling it's Nasal Spray vaccine, Flu Mist designed to maybe, prevent Swine Flu.   "Nearly five million doses of an H1N1 swine flu vaccine were […]


Flumist with Toxins for Canadians 2010 Flu Season
  by thetruthergirls
Canadians To Be Vaccinated With Live H1N1 Virus with MSG For The 2010/11 Flu Season Dave Mihalovic Prevent Disease http://preventdisease.com September 23, 2010 The Public Health Agency of Canada has once again given […]



Other reviews about FluMist on web:

Learn about FluMist® (Influenza Vaccine Live, Intranasal) FluMist(R) (Influenza Vaccine Live, Intranasal)


FluMist is a nasal spray influenza vaccine manufactured by MedImmune, Inc. that was first introduced in 2003. It was the first and (as of 2007) the only live attenuated vaccine ... FluMist - Wikipedia, the free encyclopedia


LAIV (FluMist®) is approved for use in healthy* people 2-49 years of age who are not pregnant. Who should not be vaccinated with the nasal-spray flu vaccine LAIV (FluMist®)? CDC - Seasonal Influenza (Flu) - Q & A: The Nasal-Spray Flu ...


FluMist. Proper Name: Influenza Vaccine Live, Intranasal Tradename: FluMist Manufacturer: MedImmune, LLC, License #1799 Indications: For the active immunization of individuals ... FluMist


Learn about the prescription medication FluMist (Influenza Virus Vaccine), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. FluMist (Influenza Virus Vaccine) Drug Information: Uses, Side ...


Flumist (influenza virus vaccine) is a vaccine nasal spray used to prevent infection caused by influenza virus. Includes Flumist side effects, interactions and indications. Flumist Information from Drugs.com


All about FluMist. View complete and up to date FluMist information - part of the Drugs.com trusted medication database. FluMist Facts and Comparisons at Drugs.com


FluMist isn't for every child, but it is a good option to consider in getting your child vaccinated against the flu if he is older than age 2 and doesn't have any health problems. FluMist vs. a Flu Shot


Find out all about flumist, including the most common uses, side effects, interactions and risk factors from leading medical experts. Flumist - a comprehensive view - Wellsphere


FluMist, a nasal spray flu vaccine, is an alternative to flu shots in healthy people who want to avoid getting sick with influenza but don't want a shot. FluMist Nasal Spray Flu Vaccine





Featured Reviews

Reviews Novolin R

Novolin R Drug Description Novolin® R Regular, Human Insulin Injection (recombinant DNA origin) USP DRUG DESCRIPTION Novolin® R Regular, Human Insulin Injection (rDNA origin) USP is a polypeptide hormone structurally identical...
Read More  |  Review This
Reviews K-Tab

K-Tab Drug Description K-Tab® (potassium chloride) Extended-Release Tablets USP DRUG DESCRIPTION K-TAB (potassium chloride extended-release tablets) is a solid oral dosage form of potassium chloride containing 750 mg of potassium chloride,...
Read More  |  Review This
Reviews Cycloset

Cycloset Drug Description CYCLOSET (bromocriptine mesylate) Tablets, Oral DRUG DESCRIPTION CYCLOSET Tablets contain bromocriptine mesylate, a dopamine receptor agonist. Bromocriptine mesylate is chemically designated [Ergotaman-3',6',18-trione, ...
Read More  |  Review This
Reviews Diabinese

Diabinese Drug Description DIABINESE® (chlorpropamide) Tablets, USP For Oral Use DRUG DESCRIPTION What are the possible side effects of chlorpropamide (Diabinese)? Stop taking chlorpropamide and seek emergency medical attention...
Read More  |  Review This
Reviews Desmopressin Acetate Rhinal Tube

DDAVP Rhinal Tube Drug Description DDAVP® Rhinal Tube (desmopressin acetate) DRUG DESCRIPTION What are the possible side effects of desmopressin nasal (DDAVP Nasal, DDAVP Rhinal Tube, Stimate)? Get emergency medical help if...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....